Recruiting
Non-small cell lung cancer
RecruitingStudy of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation
Registered drug
Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation
Registered drug
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+3
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Carboplatin




